Mosaic Biosciences to Present Poster on Extended-Duration Fusion Proteins at ARVO 2025

May 4, 2025 08:00 AM Eastern Daylight Time

BOULDER, Colo.-- Mosaic Biosciences, a biotechnology company working with partners to discover next-generation biologics for ocular disease, today announced it will present a poster at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place May 4–8, 2025, in Salt Lake City, Utah.

The presentation will highlight novel fusion proteins engineered for extended intraocular half-life, aiming to reduce injection frequency in retinal vascular diseases.

Poster Details

• Title: Novel Engineered Proteins With Large Hydrodynamic Radius to Enhance Vitreal Pharmacokinetics
• Authors: Eric Furfine, Nikki Collins, Tristan Woods, Marion Weir, Hanna Barrett, Ryan Pepi, Joseph Grim
• Location: Salt Palace Convention Center, Salt Lake City, Utah

“Current therapies require frequent intravitreal injections, which can be a major burden for patients and caregivers,” said Dr. Eric Furfine, Chief Executive and Scientific Officer at Mosaic Biosciences. “Our engineered fusion proteins and antibodies demonstrate promising pharmacokinetics and bioactivity that could support extended dosing intervals up to 20 weeks.”

Highlights of the poster include:

• Protein engineering strategies to increase hydrodynamic radius of proteins and antibodies
• The technology was demonstrated using aflibercept as a model system
• In vitro VEGF binding and bioactivity comparable to aflibercept
• Preclinical data showing 1.5–1.8× longer vitreal half-life
• PK/PD modeling suggesting durable efficacy with infrequent dosing

To view the poster, please visit: Mosaic ARVO 2025 poster.

About Mosaic Biosciences, Inc.

Mosaic Biosciences is pioneering a transformative model for drug discovery, offering biotech, biopharma, and academic institutions a fully integrated platform for therapeutic discovery, characterization, and optimization, specializing in protein therapeutics. Mosaic’s approach seamlessly incorporates essential screening, such as developability assessment and advanced cell-based assays, into the discovery process, ensuring that potential therapeutics are evaluated for their practical application from the outset. Mosaic’s partners also benefit from rapid evaluations of animal pharmacokinetic and pharmacodynamic studies, allowing for swift decision-making. With access to cutting-edge proprietary tools and data-driven methodologies, Mosaic’s nimble, multidisciplinary team of experienced scientists collaborates closely with partners to deliver innovative solutions to modern drug discovery. United by a shared commitment to advancing human health, Mosaic empowers partners to achieve therapeutic breakthroughs efficiently and effectively.

For more information on Mosaic Biosciences, please contact: Tracey Mullen [email protected]